Diversity pattern of Duffy binding protein sequence among Duffy-negatives and Duffy-positives in Sudan by Hoque, Mohammad Rafiul et al.
Hoque et al. Malar J  (2018) 17:297  
https://doi.org/10.1186/s12936-018-2425-z
RESEARCH
Diversity pattern of Duffy binding 
protein sequence among Duffy-negatives 
and Duffy-positives in Sudan
Mohammad Rafiul Hoque1†, Mohammed Mohieldien Abbas Elfaki2,3†, Md Atique Ahmed1†, Seong‑Kyun Lee1, 
Fauzi Muh1, Musab M. Ali Albsheer2, Muzamil Mahdi Abdel Hamid2* and Eun‑Taek Han1* 
Abstract 
Background: Vivax malaria is a leading public health concern worldwide. Due to the high prevalence of Duffy‑neg‑
ative blood group population, Plasmodium vivax in Africa historically is less attributable and remains a neglected dis‑
ease. The interaction between Duffy binding protein and its cognate receptor, Duffy antigen receptor for chemokine 
plays a key role in the invasion of red blood cells and serves as a novel vaccine candidate against P. vivax. However, the 
polymorphic nature of P. vivax Duffy binding protein (DBP), particularly N‑terminal cysteine‑rich region (PvDBPII), rep‑
resents a major obstacle for the successful design of a DBP‑based vaccine to enable global protection. In this study, 
the level of pvdbpII sequence variations, Duffy blood group genotypes, number of haplotypes circulating, and the 
natural selection at pvdbpII in Sudan isolates were analysed and the implication in terms of DBP‑based vaccine design 
was discussed.
Methods: Forty‑two P. vivax‑infected blood samples were collected from patients from different areas of Sudan 
during 2014–2016. For Duffy blood group genotyping, the fragment that indicates GATA‑1 transcription factor bind‑
ing site of the FY gene (− 33T > C) was amplified by PCR and sequenced by direct sequencing. The region II flanking 
pvdbpII was PCR amplified and sequenced by direct sequencing. The genetic diversity and natural selection of pvdbpII 
were done using DnaSP ver 5.0 and MEGA ver 5.0 programs. Based on predominant, non‑synonymous, single nucleo‑
tide polymorphisms (SNPs), prevalence of Sudanese haplotypes was assessed in global isolates.
Results: Twenty SNPs (14 non‑synonymous and 6 synonymous) were identified in pvdbpII among the 42 Sudan P. 
vivax isolates. Sequence analysis revealed that 11 different PvDBP haplotypes exist in Sudan P. vivax isolates and the 
region has evolved under positive selection. Among the identified PvDBP haplotypes five PvDBP haplotypes were 
shared among Duffy‑negative as well as Duffy‑positive individuals. The high selective pressure was mainly found on 
the known B cell epitopes (H3) of pvdbpII. Comparison of Sudanese haplotypes, based on 10 predominant non‑syn‑
onymous SNPs with 10 malaria‑endemic countries, demonstrated that Sudanese haplotypes were prevalent in most 
endemic countries.
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Background
Vivax malaria is a leading public health concern world-
wide [1]. Out of 6 malaria parasites that infect humans, 
Plasmodium vivax is the second lethal cause of infec-
tion after Plasmodium falciparum, which is widely 
distributed in malaria-endemic regions where approxi-
mately 2.85 billion people are at risk [2]. Although 
global malaria cases are on the decline over the years, 
with the emergence of drug-resistant P. vivax strains 
and associated severe and fatal consequences and 
the ability to produce hypnozoites causing relapse in 
patients, there are clear indications of notable public 
health significance [3–7]. Eradication and control inter-
ventions targeting P. falciparum are supposed to not be 
fully effective against P. vivax which is certainly a major 
challenge for malaria eradication [8]. Therefore, there is 
an urgent need for a vaccine against this deadly parasite 
[9].
Plasmodium vivax invasion is primarily dependent 
on the interaction between Duffy binding protein and 
its corresponding receptor Duffy antigen receptor for 
chemokines (DARC) [10]. Recently there are confirmed 
P. vivax infections among Duffy-negative population, 
indicating alternate invasion pathways [11–13]. There-
fore, P. vivax Duffy binding protein (PvDBP) is a novel 
vaccine candidate because it induces strong immune 
responses in humans, and anti-DBP antibodies inhibit 
DBP–DARC interaction in  vitro and also block mero-
zoite invasion of human erythrocytes [14].
The erythrocyte-binding motif of DBP resides in the 
N-terminal cysteine-rich domain (C1–C12) known as 
DBPII [15]. However, the critical binding motif is a 170 
amino acid (291–460 aa) stretch within the 330 aa of 
DBPII, which includes cysteines C4–C7 [16]. Success-
ful invasion engages dimerization between 2 DBP and 
2 DARC molecules [17]. Similar to other blood stage 
adhesion ligands, DBPII resides under strong immune 
selective pressure [18]. PvdbpII region is highly poly-
morphic with 4 times higher substitution rate com-
pared to the rest of the gene, and polymorphisms at 
certain residues were found to be consistent in global 
pvdbpII isolates, demonstrating that polymorphisms 
help in immune evasion mechanism [19, 20]. Although 
such polymorphism is not known to affect the host-
parasite binding, anti PvDBP antibodies, detected in 
residents of malaria-endemic areas, recognize PvDBPII 
but reveal significant differences regarding inhibitory 
responses [18].
The variable nature of the PvDBP, in particular DBPII, 
is a major challenge to the development of a vaccine 
against vivax malaria, restricting strain-transcending 
global protection [21]. The haplotype analysis using 
global pvdbpII sequences previously identified 7 haplo-
types that can cover 60% parasite population in 8 malaria-
endemic countries [22]. Such knowledge is important for 
the rational design of DBP-based vaccine against vivax 
malaria. However, existing data lack the information of 
DBP sequence polymorphism originating from an Afri-
can country such as Sudan, as African P. vivax studies 
are neglected because of the high burden of P. falciparum 
cases and a high percentage of Duffy-negative population, 
which is usually thought to serve as a selective barrier to 
P. vivax infection [23]. Moreover, several studies revealed 
that P. vivax infection in African countries is not as low 
as was considered before [24]. High numbers of imported 
cases of P. vivax have also been documented in Chinese 
workers returning from African countries [25, 26]. Addi-
tionally, around 86.6 million Duffy-positive individuals 
were at risk in sub-Saharan countries; more attention to 
P. vivax in Africa is needed to control this parasite [24]. 
A recent study showed a 35.6% P. vivax infection rate in 
Central Sudan, indicating great public health significance 
of this neglected parasite [27]. However, there is no study 
of DBP sequence polymorphism from Sudan.
This study was conducted to determine the haplotype 
diversity of pvdbpII and Duffy blood group genotyping, 
natural selection of Sudanese pvdbpII and the haplotype 
prevalence based on predominant, non-synonymous sin-
gle nucleotide polymorphisms (SNPs) in other endemic 
countries worldwide. The implication in terms of a DBP-
based vaccine design is discussed.
Methods
Blood sample collection and DNA preparation and species 
identification by PCR
Sixty-three blood spots in Whatman filter papers were 
collected from cross-sectional surveys between 2014 and 
2016 during the malaria transmission season (August to 
February) from malaria patients attending hospitals or 
health facilities in Sudan (Additional file  1). Initially, all 
Conclusion: This is the first pvdbp genetic diversity study from an African country. Sudanese isolates display high 
haplotype diversity and the gene is under selective pressure. Haplotype analysis indicated that Sudanese haplotypes 
are a representative sample of the global population. However, studies with a large number of samples are needed. 
These findings would be valuable for the development of PvDBP‑based malaria vaccine.
Keywords: Malaria, Plasmodium vivax, Sudan, Haplotype, Genetic diversity
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samples were screened by rapid diagnostic kit (RDT) and 
microscopy for P. vivax infection. Genomic DNA was 
extracted using a QIAamp Blood Mini Kit Qiagen, Valen-
cia, CA, USA) and kept at − 20 °C until used. Then Plas-
modium species were identified by 18SrRNA gene-based 
nested PCR using genus and species-specific primers as 
described previously [28].
Duffy genotyping
A 252  bp fragment, which indicates GATA-1 transcrip-
tion factor binding site of the FY gene (− 33T > C), was 
amplified using nested PCR. The primers were used as 
follows: Nest 1 Duffy_F: 5′-GGA TGG AGG AGC AGT 
GAG AG-3′ and Nest 1 Duffy_R: 5′-CAA AGG GAG GGA 
CAC AAG AG-3′; Nest 2 Duffy_F: 5′-TAG TCC CAA CCA 
GCC AAA TC-3′ and Nest 2 Duffy_R: 5′-TCA CCC TGT 
GCA GAC AGT TC-3′. PCR amplification was performed 
using an Accupower premix (Bioneer, Daejeon, Korea) 
in a final volume of 20  µL containing 200  pM of each 
primer, 250  µM of each deoxyribonucleoside triphos-
phate, 1.5  mM  MgCl2, 10  mM Tris-hydrochloric acid 
(pH 9.0), 30  mM KCl, 1.0 units of Taq polymerase and 
2  µL of genomic DNA template. For nest 1 PCR reac-
tion, the cycling conditions were: initial denaturing at 
94  °C for 5 min followed by 35 cycles of 94  °C for 30 s, 
59 °C for 1 min, and 72 °C for 45 s, and a final extension 
step of 10 min at 72  °C. The nest 2 primers were added 
with the nest 1 amplicons and amplified using the similar 
conditions except that the extension time of 25 s at 72 °C 
during 35 cycles. PCR products were analysed by electro-
phoresis on 1% agarose gel stained with 0.05% Redsafe 
dye (iNtRON Biotechnology, Daejeon, Korea). Ampli-
cons were gel purified using DNA purification kit (Mach-
erey–Nagel, Germany) as per manufacturer’s instruction. 
Purified products were sequenced in two directions using 
Nest 2 Duffy_F and Nest 2 Duffy_R primers by commer-
cial sequencing company (Genotech, Daejeon, Korea) for 
genotyping. Sequences were aligned with NCBI refer-
ence Sequence: NG_011626.3 to detect a polymorphism 
(− 33T → C) for genotype confirmation.
PCR amplification and sequencing
The region flanking P. vivax dbpII fragment (nucleotide 
positions 586–1848 bp; aa 196–617) was amplified using 
nested PCR. Nest 1 forward and reverse primers were 
Nest 1_F: GAT AAA ACT GGG GAG GAA AAA GAT and 
Nest 1_R: CCC GTA ACA GCT TTA CCT G, respectively. 
Nest 1 PCR amplification was performed using an Accu-
power premix (Bioneer, Daejeon, Korea) in a final volume 
of 20  µL containing 200  pM of each primer, 250  µM of 
each deoxyribonucleoside triphosphate, 1.5  mM  MgCl2, 
10 mM Tris-hydrochloric acid (pH 9.0), 30 mM KCl, 1.0 
units of Taq polymerase and 3.5  µL of genomic DNA 
template. PCR cycling conditions were performed as fol-
lows: initial denaturing at 94 °C for 5 min followed by 35 
cycles of 94  °C for 30  s, 59.6  °C for 30  s, and 72  °C for 
1 min 30 s, and a final extension step of 10 min at 72 °C. 
Nest 2 forward and reverse primers were Nest 2_F: ATG 
TTA GAT TAT GAG ACA TCT AGC AA and Nest 2_R: 
AAC AGC TTT ACC TGT GGT AGAAC, respectively. 
Then nest 2 PCR amplification was performed using the 
similar reaction condition to nest 1 with the exception 
of 4 µL of nest 1 amplicon as template and thermal pro-
file were used as follows; initial denaturing at 94  °C for 
5 min followed by 35 cycles at 94 °C for 30 s, 57.6 °C for 
30 s, and 72 °C for 1 min 30 s, and a final extension step 
of 10 min at 72 °C. PCR products were analysed by elec-
trophoresis on 1% agarose gel stained with 0.05% Redsafe 
dye (iNtRON Biotechnology, Daejeon, Korea). Ampli-
cons were gel purified using DNA purification kit (Mach-
erey–Nagel, Germany) as per manufacturer’s instruction. 
Direct sequencing was performed using Nest 2_F and 
Nest 2_R by a commercial sequencing company (Geno-
tech, Daejeon, Korea).
All sequences generated were assembled and edited 
using SeqMan and EditSeq, Lasergene v 7.0 (DNASTAR) 
and aligned using the Clustal W program in MegAlign 
Lasergene v 7.0 (DNASTAR). Samples having mixed 
genotype infections were excluded and any singleton 
site was confirmed by re-sequencing. SNPs at different 
residues were identified compared to Sal-1 (GenBank 
accession no. DQ156512) sequence as a reference. 
The sequences reported here have been deposited in 
the GenBank database under the accession numbers 
(MG805616–MG805657).
DNA sequence and polymorphism analysis
DNA sequence polymorphism analysis was investigated 
on 42 Sudan pvdbpII sequences (nt. 727–1653). Using 
the DnaSP ver. 5.10.00 [32] following genetic diversity 
parameters were analysed; a number of segregating sites 
(S), nucleotide diversity (π), haplotype diversity (Hd), and 
the average number of pair-wise nucleotide differences 
within the population (k).
To explore the effect of overall natural selection in the 
fragment and on the epitope regions, rates of synony-
mous (dS) and non-synonymous (dN) substitutions was 
investigated using Nei and Gojobori method [29] with 
Jukes and Cantor correction. Tajima’s D test [30] and Fu 
and Li’s D and F tests [31] were performed with DnaSP 
ver. 5.10.00 [32]. For epitope regions, 10 known lin-
ear B-cell epitopes, which were classified into 3 distinct 
classes, high inhibitory (H), medium (M) inhibitory and 
low (L) inhibitory, were examined for natural selection 
[18].
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Analysis of predominant pvdbpII nucleotide haplotypes
In order to determine whether Sudanese haplotypes were 
prevalent in other endemic countries, 10 predominant 
non-synonymous SNPs were used, and these haplotypes 
were compared with haplotype data from 10 endemic 
countries (Mexico, Colombia, Brazil, Iran, India, Sri 
Lanka, Myanmar, Thailand, South Korea, Papua New 
Guinea).
Sequences used in this study for analysis
Papua New Guinea (n = 113), (DQ156519; AF289480–
AF289483; AF289635–AF289653 and AF291096; 
AY970837–AY970925, AF469515–AF469602); Colom-
bia (n = 17), (U50575–U50590 and DQ156513); South 
Korea (n = 15), (DQ156515; DQ156522–DQ156523; 
AF215737–AF215738; AF220657, AF220659–
AF220667); India (n = 100), (FJ491142–FJ491241); 
Thailand (n = 30), (EF219451, EF368159–EF368180, 
EF379127–EF379132, EF379134); Sri Lanka (n = 100), 
(GU143914–GU144013); Brazil (n = 123), (DQ156520, 
EU812839–EU812960); Iran (n = 11) (EU860428–
EU860438); Myanmar (n = 12), (JN255576–JN255587); 
Mexico (n = 35), (KP759780–KP759814).
Results
Duffy genotypes
Duffy genotyping was performed to the isolates (n = 42) 
that could successfully amplify pvdbpII and generate 
high-quality sequences. Among those 42 P. vivax-infected 
patients, 35 (83.3%) were Duffy positive (Homologous 10 
and Heterozygous 25) and 7 (16.7%) were Duffy negative 
(Fig. 1a).
Fig. 1 PvdbpII haplotypes and Duffy blood antigen genotypes observed among Sudanese isolates. a Polymorphic amino acid residues are listed 
for each haplotype. Amino acid residues identical to the reference sequence, Sal‑1 (DQ156512), are marked with no color, dimorphic amino acid 
changes in grey and trimorphic in black. A total number of sequences for each pvdbpII haplotype and Duffy blood antigen genotype are listed in 
the right panel. b Frequencies of amino acid changes found in PvDBPII among Sudanese isolates
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Genetic polymorphism of PvDBPII
Out of the 63 Sudanese isolates, the pvdbpII gene was 
successfully PCR amplified from 54 isolates. High-quality 
sequencing results for the PvDBPII fragments (927  bp) 
were obtained from 42 isolates, which were taken for 
further analysis. DNA sequence analysis of the 42 pvdb-
pII sequences showed that there was no size variation 
among the sequences compared to reference Sal-1 strain 
sequence. Twenty SNPs were found, 6 (30.0%) of which 
were synonymous and 14 (70.0%) were non-synonymous 
substitutions. Of these 20 SNPs, 7 occurred at the first 
base of the codon, 5 at the second, and 8 at the third base 
of the codon, resulting in significant amino acid changes 
in protein level (Fig. 1a). Among these, 2 singleton non-
synonymous substitutions were detected (D497N and 
T513K). Five synonymous sites were found in 2.4% R408, 
2.4% I380, 7.1% Q432, 2.4% A514, and 2.4% N531. Align-
ment of deduced amino acid sequences revealed 11 dif-
ferent haplotypes (haplotype 1–11) with amino acid 
changes at 14 positions in which one showed trimorphic 
polymorphism (K386N/Q) and the others were dimor-
phic (Fig.  1a). Duffy-negative P. vivax isolates reside in 
6 different haplotypes out of 11 haplotypes (Fig. 1a). Of 
the 14 non-synonymous substitutions, 13 were reported 
in the previous study in the parasites circulating in dif-
ferent parts of the world, whereas one point muta-
tion was found unique to current study (D497N, 2.4%,) 
[33–35]. All 12 cysteine residues were conserved among 
the 42 Sudanese isolates. Moreover, among all non-syn-
onymous sites, frequency of residues K371E (47.6%), 
D384G (73.8%), N417K (76.2%), L424I (88.1%), W437R 
(76.2%), and I503K (85.7%) were higher than remaining 
sites (Fig. 1b). However, haplotype 1 was found dominant 
(26.2%) among other haplotypes (Fig.  1a). Comparison 
of the most common amino acid variants observed glob-
ally in PvDBPII revealed that Sudan isolates showed a 
comparatively similar pattern of minor allele frequency 
to Mexico isolates, but differed from other countries iso-
lates (Papua New Guinea, Colombia, Brazil, Iran, India, 
Sri Lanka) (Table 1). Although Mexican isolates showed 
similar amino acid changes compared to Sudan isolates, 2 
variants found in the Sudan isolates (D497N and T513K) 
were not identified in Mexican isolates [36].
Haplotype diversity and comparison with global 
populations
Based on the most common 10 non-synonymous SNPs 
observed globally, 8 haplotypes were found in Sudan 
(Additional file  2). The distribution of these haplotypes 
in 10 P. vivax endemic countries worldwide showed 
that all countries had at least one Sudanese haplotype, 
(Haplotype 4 in Colombia) and maximum 6 Haplotypes 
(Haplotype 1, 2, 3, 4, 6, and 9 in Sri Lanka) (Fig. 2) cov-
ering varied frequencies of parasite population, with the 
highest in Mexico (Haplotype 1, 2, 4 and 6, 91.4%) and 
lowest in Papua New Guinea (Haplotype 3 and 9, 1.8%) 
(Fig. 2). In a previous study, seven haplotypes were iden-
tified to cover an overall 60.0% worldwide parasite popu-
lation but without any African countries [22]. Three of 
Table 1 Minor allele frequencies of the most common PvDBPII amino acid variants
a The first letter represents the amino acid in that position in the Sal-1 sequence and the other letter represents the substituted amino acid; b [36]; c [22]; d [34]; e [35]; f 
[33]; g [42]
Isolate PvDBPII variants forms on 10 non-synonymous  positiona
R308S K371E D384G E385K K386N H390R N417K L424I W437R I503K
Sal‑1 AGG AAA GAT GAA AAG CGT AAT TTA TGG ATA 
Variant AGT GAA GGT AAA AAT CAT AAA ATA CGG AAA
Country Frequency
 Sudan 19.0 47.6 73.8 19.0 19.0 16.2 76.2 88.1 76.2 85.7
 Mexicob 17.1 20.0 31.4 17.1 17.1 11.4 88.6 88.6 85.7 91.4
 Colombiac 0.0 17.6 41.2 17.6 17.6 94.1 41.2 41.2 11.8 5.9
 Brazilc 7.3 26.0 18.7 20.3 22.8 50.4 39.8 48.0 48.8 43.1
 Myanmard 22.2 22.2 85.2 33.3 33.3 63.0 38.9 83.3 61.1 77.8
 Sri  Lankae 13.0 34.0 94.0 20.0 20.0 66.0 36.0 49.0 37.0 55.0
 Indiac 10.0 33.0 87.0 31.0 31.0 65.0 38.0 45.0 38.0 47.0
 Thaif 26.7 20.0 76.7 46.6 40.0 56.6 36.6 86.7 63.3 56.7
 Koreac 0.0 46.7 46.7 6.7 6.7 53.3 93.3 100 100 100
 Irang 6.6 17.3 61.3 6.7 6.6 41.3 44.0 50.6 45.3 70.6
 PNGc 69.0 11.5 34.5 9.7 9.7 50.4 33.6 68.1 32.7 42.5
Average 17.4 26.9 59.1 20.7 20.3 51.6 51.5 68.1 54.5 61.4
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the haplotypes in the present study (Haplotype 1, 2 and 
6) were shared with those haplotypes.
Nucleotide diversity and natural selection of pvdbpII
Analysis of molecular polymorphism within the 42 
pvdbpII sequences revealed lower nucleotide diversity 
(π = 0.00497) and higher haplotype diversity (Hd = 0.900) 
which was similar to the diversity indices from several 
endemic countries [35]. Sliding window plot (window 
length 100 bp, step size 20 bp) using the DnaSP, revealed 
that nucleotide diversity was highest at 300–650 nt posi-
tion of pvdbpII (Fig.  3). A significant positive natural 
selection (dN − dS = 2.05, p < 0.05) was found within the 
Sudanese pvdbpII sequences.
Fig. 2 Worldwide prevalence of Sudanese pvdbpII haplotypes. The frequencies of 8 haplotypes based on 10 common non‑synonymous 
polymorphic sites (Additional file 2) are depicted as pie charts and mapped to their geographic origin. Coloured segments indicate shared 
haplotypes with Sudan (dark blue = Haplotype 1, Sudan n = 11, Brazil n = 8, Iran n = 2, South Korea n = 5, Sri Lanka n = 2, Thai n = 1; bright 
green = Haplotype 2, Sudan n = 7, Brazil n = 2, Sri Lanka = 1, India n = 1; red = Haplotype 3, 5, 11 Sudan n = 12, Iran n = 1, PNG n = 1, Sri Lanka n = 6, 
Thai n = 1, India n = 7, Myanmar n = 1; Gold = Haplotype 4, Sudan n = 5, PNG n = 1, India n = 1; purple = Haplotype 6, 10 Sudan n = 4, Brazil n = 23, 
Iran n = 2, Sri Lanka n = 44, Thai n = 1, India n = 29; orange = Haplotype 7, Sudan n = 1, Brazil n = 18, Colombia n = 1, Sri Lanka n = 3, Thai n = 2, 
India n = 12, Myanmar n = 2; n = 1 and pink = Haplotype 8, Sudan n = 1, India n = 7; brown = Haplotype 9 Sudan n = 1 South Korea n = 1; Sri Lanka 
n = 1) and grey indicates other haplotypes to respective population. Note that haplotypes 5 and 11, and 10 correspond to haplotypes 3 and 6, 
respectively, because 10 non‑synonymous SNPs out of 14 non‑synonymous SNPs (Fig. 1a) were considered in this analysis
Fig. 3 Graphical representation of pvdbpII nucleotide diversity 
(π). Sites with alignment gaps were not counted in the window 
length, window length: 100, and step size: 20
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Polymorphisms related to B- and T-cell epitopes
Analysis of natural selection in 10 known B-cell epitopes 
regions within Sudanese isolates indicated that the H3 
epitope (residues 384–399 aa) was under positive selec-
tion (Table 2) whereas H2, M1, L1, L2, and L4 epitopes 
were conserved among the 42 Sudanese isolates (Table 2). 
The nucleotide diversity at epitope H3 was also high.
Discussion
Plasmodium vivax, the widely distributed malaria para-
site is a great public health concern. A broadly effective 
malaria vaccine is a powerful tool for the control, elimi-
nation and eradication of this deadly disease [21]. Sci-
entists across the globe are searching for a good strategy 
that provides strain transcending as well as long-term 
protection. However, the high degree of diversity of para-
site antigens and the strain-specific immune response are 
challenging issues in the success of malaria vaccines [18]. 
In the current study, the genetic diversity and natural 
selection of DBPII have been investigated among Suda-
nese P. vivax isolates, and this is the first report of any 
African origin P. vivax isolates.
Based on amino acid variants, 11 different PvDB-
PII haplotypes were identified in the Sudanese isolates. 
Except for one unique haplotype (Haplotype 11), the 
majority of the haplotypes identified in this study were 
previously reported from other geographical areas (Mex-
ico, Brazil, Iran, India, Sri Lanka, Thailand, South Korea) 
[22, 33–36]. Haplotype 1 was found to be the most preva-
lent in Sudanese isolates. Haplotype analysis showed that 
the number of identified haplotypes among Sudanese P. 
vivax isolates (26.2%) was higher than those previously 
reported from Mexico (22.9%) and Myanmar (22.2%) [34, 
36], but it was lower than those reported from Sri Lankan 
(33.0%) and Brazilian (27.9%) isolates [35, 37].
Although Duffy negativity act as a selective barrier for 
P. vivax infection, few studies reported Duffy-negative P. 
vivax infection from several African countries [11–13]. 
Interestingly, in the current study, 7 Duffy-negative P. 
vivax cases were found, and they reside into six PvDBP 
haplotypes. However, it was found that 5 PvDBP hap-
lotypes were shared among Duffy-negative as well as 
Duffy-positive individuals, except for one haplotype 
(Fig. 1a), which was unique to a Duffy-negative individ-
ual. Moreover, the 2 PvDBP Malagasy haplotypes from 
2 Duffy-null individuals were also not identical to any of 
the haplotypes found in Sudan [38]. The findings of the 
shared PvDBP haplotypes between Duffy-positive and 
Duffy-negative individuals raise the question whether 
they have a role in P. vivax infection in Duffy-null individ-
uals or not? The previous study reported that mutations 
in PvDBP did not relate to the ability of P. vivax to infect 
Duffy-null individuals [38]. An expansion of PvDBP copy 
number in Duffy-null P. vivax infection was documented 
which might allow binding the DBP with another ligand 
on Duffy-null erythrocyte [38]. Further PvDBP haplotype 
diversity, as well as a functional study with a large number 
of P. vivax isolates infecting Duffy-negative individuals 
will be needed to elucidate the exact function of shared 
haplotypes between Duffy-positive and Duffy-negative 
individuals and their role in P. vivax infection. Among 
the 14 non-synonymous mutations identified in the cur-
rent study, 13 were previously reported, whereas the 
D497N was unique to Sudan isolates [33–37]. It was also 
found that all 12 cysteine residues were conserved, indi-
cating the conserved binding ability to host erythrocytes 
in the field. However, previous studies revealed that these 
non-synonymous mutations do not affect the binding to 
the erythrocyte receptor but rather promote the parasite 
for immune evasion [18]. Three residues, N417K, W437R 
and I503K forming an important discontinuous epitope 
in PvDBP, were described as the main target for binding 
inhibitory antibodies against erythrocyte binding [39–
41]. In the present study, N417K (76.2%), W437R (76.2%) 
and I503K (85.7%) were detected and these 3 SNPs were 
found simultaneously among 35 isolates (83.3%), which 
suggests a strong association between these residues in 
Sudanese P. vivax isolates. The frequency of these 3 SNPs 
was similar to that reported from Mexico but different 
from Sri Lanka, Colombia, Iran, and Myanmar [19, 34, 
35, 42].
Many previous pvdbpII diversity studies documented 
high rates of non-synonymous mutations relative to 
synonymous mutations (dN − dS > 1.9) that reflected a 
positive natural selection promoting greater diversity of 
pvdbpII, probably to avoid host immune responses irre-
spective of the geographical distribution [18]. In this 
study, analysis of natural selection within the 42 Suda-
nese P. vivax isolates also identified significant positive 
selection (dN − dS = 2.05, p < 0.05). These results indicate 
that by increasing polymorphisms within the pvdbpII, 
parasites escape from the host immune response [18]. 
Natural selection in the known B-cell epitope regions in 
Sudanese isolates indicated that only H3 epitope (aa 384–
399) was found to be under strong positive selection that 
could generate greater diversity. Higher genetic diversity 
was also found in the H3 epitope region. Tajima’s D, Fu 
and Li’s  D*, and Fu and Li’s  F* for the H3 epitope region 
was positive but not significant. Similar strong selection 
pressure in this epitope region was observed in Sri Lan-
kan and Iranian isolates [35, 42].
The number of migrant workers from P. vivax-
endemic countries has risen in most African countries, 
including Sudan [27, 43]. Recently, P. vivax infections 
have been reported in high numbers in Sudan. This 
rising trend is possibly due to human migration from 
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several Asian and African countries to work at newly 
formed petroleum and sugar companies in Sudan [27]. 
It was hypothesized that Sudanese pvdbpII haplotype 
might be a representative sample of global P. vivax 
population and this information could be used for the 
rational design of a PvDBP-based multi-allele vaccine. 
On this basis, haplotypes were generated considering 
10 most frequent polymorphism sites of pvdbpII and 
8 haplotypes were identified from Sudanese P. vivax 
isolates (Additional file  2). The prevalence of these 8 
haplotypes was observed in all 10 malaria-endemic 
countries with a variable frequency that covers the 
highest 91.4% parasite population in Mexico and low-
est in Papua New Guinea (1.8%) (Fig. 2), with an overall 
coverage of 36.8% (Fig. 2). However, haplotype analysis 
from seven endemic countries (Mexico, Brazil, Iran, 
India, Sri Lanka, Thailand, South Korea) indicated that 
haplotypes from Sudan covered up to 50% parasite 
populations. The current study was conducted using 
a low number of samples from Sudan (n = 42) and the 
information generated can be considered preliminary, 
yet it was representative of global P. vivax population 
and further studies with a large number of samples 
from Sudan is required to come to conclusions. In the 
current study among the identified haplotypes, none 
was identical to the Sal-1 isolate, which was also found 
absent in Thailand [22]. However, several studies from 
other malaria-endemic countries documented Sal-1 at 
low frequencies [22]. Although a phase 1 trial of PvDBP 
vaccine based on the Sal-1 sequence has been reported 
[44] it might be an inefficient strategy because it cov-
ers only 10% of the worldwide samples [22]. To cover 
the major portion of the P. vivax population multi-
allele PvDBP might be a good approach. In a previous 
study, a similar multi-allele vaccine strategy with a min-
imum number of haplotypes using worldwide pvdbpII 
sequences identified seven haplotypes that covered an 
overall 60% worldwide parasite population but without 
any African countries [22]. In this study, out of 8 Suda-
nese haplotypes, 3 haplotypes were shared with that 
previous study those were (haplotypes 1, 6 and 7) sug-
gested for multi-allele DBP vaccine approach.
Conclusions
The findings provide the first description of genetic poly-
morphism and natural selection of pvdbpII in Sudan P. 
vivax isolates. Further investigations using a large num-
ber of isolates from different regions of Sudan and other 
African countries are needed to know the diversity of 
pvdbp, which is important to design and develop a DBP-
based vaccine.
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